Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Luminex Corporation has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners and 2 distinct art units, showing that the company's prosecution efforts are distributed across multiple points of review. This distribution suggests that the company is pursuing several distinct biotechnological innovations. The presence of 3 pending office actions indicates a multi-faceted approach to building the company's intellectual property portfolio.
The busiest examiner for the portfolio is GRAY, JESSICA, who handles 1 busiest examiner pending office action. Since each of the 3 pending office actions is assigned to a different examiner, the company must navigate the specific procedural preferences of 3 separate individuals. For the patent practitioner, this decentralized structure requires a flexible strategy, as the arguments successful with one examiner may not resonate with the others. The lack of concentration under a single examiner means that the portfolio's overall success is not tied to any one individual's discretion but rather to a broader range of office interactions across the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| KIM, YOUNG J | 1 | 64.8% | +18.1% |
| SISSON, BRADLEY L | 1 | 19.7% | +20.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17808180 | METHODS AND COMPOSITIONS FOR DISCRETE MELT ANALYSIS | SISSON, BRADLEY L | 56d |
| 18062918 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS | GRAY, JESSICA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17820277 | DIGITAL AMPLIFICATION ASSAY ANALYSIS METHOD | KIM, YOUNG J | 8d overdue |
| 17808180 | METHODS AND COMPOSITIONS FOR DISCRETE MELT ANALYSIS | SISSON, BRADLEY L | 56d |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18062918 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS | GRAY, JESSICA | 1682 | §112DP | Final Rejection | — | Pending | Dec 07, 2022 |
| 17820277 | DIGITAL AMPLIFICATION ASSAY ANALYSIS METHOD | KIM, YOUNG J | 1681 | Other | Final Rejection | 8d overdue | Pending | Aug 17, 2022 |
| 17808180 | METHODS AND COMPOSITIONS FOR DISCRETE MELT ANALYSIS | SISSON, BRADLEY L | 1682 | §103§112Other | Final Rejection | 56d | Pending | Jun 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial